Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.
The company operates as a generic formulation manufacturer with no discernible mechanism for pricing power or high switching costs, as evidenced by average ROCE and ROE figures that barely exceed the cost of capital. While revenue growth is strong, the lack of proprietary brands or unique distribution advantages keeps them in a commoditized segment of the pharmaceutical market.
Earnings are primarily reinvested into capacity expansion, such as the new injectable facility, though the cash conversion ratio of 0.52 suggests significant capital is tied up in working capital. The company has recently amended its charter to allow diversification into unrelated fields like real estate and power generation, which is a negative signal for capital discipline.
The investment collapsed as management's lack of focus led to catastrophic capital misallocation. By diverting pharmaceutical profits into speculative real estate and power generation ventures, the company starved its core manufacturing of necessary upgrades while failing to achieve scale in unrelated industries. This diversification, combined with a persistent inability to convert paper profits into actual cash, resulted in a liquidity crunch. As the commoditized generic market faced pricing pressure, the company's thin margins evaporated, leaving shareholders with a bloated, unfocused conglomerate that destroyed value through mediocre returns on invested capital.
RichFakir rates Syncom Formulations (India) Ltd's business quality as decent — 57/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Syncom Formulations (India) Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Syncom Formulations (India) Ltd is: Watch — wait for price. A decent business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Syncom Formulations (India) Ltd's fair value is about ₹10 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →